KOSDAQBiotech & Pharma180400

Dx & Vx

₩1,968▼ 1.60%2026-11-18 close
Market Cap
₩193.7B
Turnover
₩32,622,063
Volume
20K
Shares out.
98.4M
PER
—
PBR
2.5×
EPS
-₩204
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Narrower losses; licensing payoff is the key test

DXVX has booked operating losses for five straight quarters from the third quarter of 2025 through the third quarter of 2026, yet the third-quarter 2026 operating loss narrowed to KRW 4.13 billion from a year earlier. Its licensing deals are large on paper but carry no upfront payment, so the timing of revenue depends on milestones being reached.

  1. 1

    Revenue peaked at KRW 46.7 billion in 2023 and then fell two years in a row, to KRW 33.9 billion in 2024 and KRW 29.4 billion in 2025.

  2. 2

    Operating losses have run for three consecutive years from 2023 to 2025, and the KRW 24.3 billion loss in 2025 is the largest of the 2022–2025 period.

  3. 3

    Third-quarter 2026 revenue rose 19.3% year on year to KRW 6.69 billion, and the operating loss narrowed to KRW 4.13 billion from a year earlier.

  4. 4

    The roughly KRW 500 billion ACP technology export through a subsidiary and the roughly KRW 300 billion mRNA cancer vaccine deal carry no upfront payment, so their earnings effect will arrive stage by stage.

  5. 5

    The debt ratio fell to 61.7% at end-2025 from 342.4% a year earlier, but operating cash flow remained negative at KRW -18.9 billion.

02

Business structure

DXVX(Dx&Vx) is shifting its identity from a genetic diagnostics company to a bio-healthcare company. Its business falls into four lines.

The first is genomic diagnostics, including the genome analysis service Genome Check, which drew interest from Eastern European companies for non-invasive prenatal testing and preimplantation genetic testing at BIX 2026 held from October 28 to 30, 2026.

The second is health functional foods and healthcare products such as the Hyul-haeng Care and Liver Care lines, for which companies in the United States and parts of Europe requested quotes.

The third is China, where its subsidiary DxVx BJ, set up in 2023, reported revenue of KRW 1.48 billion and operating profit of KRW 390 million in its first year, according to a company announcement in early 2024.

The fourth is the drug pipeline, centered on an mRNA cancer vaccine, an oral obesity drug and an antiviral program.

A subsidiary, in which DXVX holds a 66.2% stake, licensed its ACP drug-delivery platform to a US biotech for roughly KRW 500 billion according to August 2025 reports, but financial terms were not disclosed. Its affiliate COREE Group was founded by the Hanmi-linked largest shareholder and provides an overseas network.

Competition overlaps with overseas genetic testing firms in diagnostics and with mRNA and oral obesity drug developers in pharmaceuticals.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩5.6B-₩6.8B−121.0%
2025Q4₩7.6B-₩2.9B−39.0%
2026Q1₩6.7B-₩5.3B−78.9%
2026Q2₩6.4B-₩6B−94.2%
2026Q3₩6.7B-₩4.1B−61.7%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩32.2B₩2.6B-₩1B8.2%−2.9%150.2%
2023₩46.7B-₩12.1B-₩27.5B−25.9%−129.8%247.0%
2024₩33.9B-₩21.6B-₩47B−63.6%−336.7%342.4%
2025₩29.4B-₩24.3B-₩29B−82.8%−30.9%61.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual results show revenue shrinking while losses widened after 2023. Revenue went from KRW 32.2 billion in 2022 to KRW 46.7 billion in 2023, up 45.2% and the largest year of the 2022–2025 period, then fell 27.4% to KRW 33.9 billion in 2024 and 13.5% to KRW 29.4 billion in 2025.

Operating profit of KRW 2.63 billion in 2022 turned into an operating loss of KRW 12.1 billion in 2023, widened to KRW 21.6 billion in 2024 and KRW 24.3 billion in 2025. The operating margin moved from 8.2% in 2022 to -25.9%, -63.6% and -82.8% over the following three years.

The company said in 2023 that it added core R&D staff and that five executives returned stock options, which affected accounting losses. Net loss attributable to controlling shareholders grew from KRW 970 million in 2022 to KRW 27.5 billion in 2023 and KRW 47 billion in 2024, then narrowed to KRW 29 billion in 2025.

Total net loss including non-controlling interests was KRW 29.6 billion in 2025, a different figure. In 2025 the operating loss widened while the controlling-shareholder loss narrowed, so the two measures moved in opposite directions, and the gap reflects non-operating items and non-controlling interests.

Operating cash flow was negative in each of 2023, 2024 and 2025, at KRW -12.1 billion, KRW -20 billion and KRW -18.9 billion.

Quarterly revenue rose from KRW 5.61 billion in the third quarter of 2025 to KRW 7.55 billion in the fourth quarter, up 34.6%, then held at KRW 6.66 billion, KRW 6.4 billion and KRW 6.69 billion through the first three quarters of 2026.

The operating loss narrowed from KRW 6.79 billion to KRW 2.94 billion, widened to KRW 5.25 billion and KRW 6.04 billion, and then narrowed to KRW 4.13 billion in the third quarter of 2026.

The controlling-shareholder net loss of KRW 3.7 billion in the third quarter of 2026 was the smallest of the last five quarters, and the last four quarters total KRW 20.1 billion.

05

Industry analysis

Demand in DXVX's end markets comes from three directions. In obesity drugs, injectable GLP-1 agents have attracted strong interest, but the company argues that their side effects such as nausea and pain create room for oral alternatives.

In infectious disease, DXVX was selected as the sole lead R&D institution for a government-funded Disease X antiviral program run with the Ministry of Health and Welfare, with roughly KRW 2.88 billion in state funding over 2026–2029.

The antiviral candidates have shown activity only at the cell level, so animal efficacy and safety remain to be verified.

In platforms, mRNA and peptide drug-delivery technologies draw licensing demand, but the earnings effect of Korean technology exports varies widely with the mix of upfront payments, milestones and royalties.

Competitively, the revenue-generating businesses in diagnostics and health foods are small, while the pipeline still needs to prove licensing results. Compared with larger listed peers in the sector, DXVX has a small revenue base of its own. The company has also said it is reviewing response options for hantavirus and Ebola.

06

Outlook

The most concrete timetable the company has recently given centers on its pipeline.

In its November 4, 2026 announcement, it set a target of filing an investigational new drug application for its oral small-molecule GLP-1 receptor agonist in the second half of 2027, after candidate selection, non-clinical safety work and clinical-grade drug production.

It said the research would be presented as a poster at ObesityWeek 2026 as a late-breaking abstract. The announcement did not include weight-loss rates or head-to-head efficacy numbers.

For the OVM-200 cancer vaccine, an August 2026 report, based on a headline, gave a target of entering Phase 2 in the first half of 2027. The antiviral program plans to fix its preclinical candidate after animal model evaluation in 2027, toxicology and API production in 2028, and an IND approval target in 2029.

Strategy is also shifting: in September 2026 the company said it would expand revenue from its own manufacturing rather than rely mainly on pipeline licensing. In China it plans to use the parent's distribution and sales network.

An earlier target for 2024 revenue of KRW 38 billion and a 25% operating margin was not met, since reported 2024 revenue was KRW 33.9 billion. A 2025 report expected milestone receipts from the preclinical mRNA vaccine program between late 2025 and early 2026. How those receipts show up in revenue is a point to check in the next periodic report.

07

Valuation

PER
—
PBR
2.5×
ROE
-52.2%
EPS
-₩204
BPS
₩837
Dividend per share
₩0

DXVX is hard to value on earnings multiples. Because the company has posted net losses over the last four quarters, its price-to-earnings ratio is not calculated. Measured against book value, the price-to-book ratio sits in a premium zone above 1x.

Market capitalization is above the controlling shareholders' equity at end-2025. Total equity rose to KRW 95.8 billion at end-2025 from about KRW 16.6 billion reported for 2024, so the asset base is thicker than before.

Whether the premium reflects pipeline value or expectations of an earnings recovery is open to interpretation. Dividends are limited while operating cash outflows continue, and the yield sits below the sector average. Against past trading ranges, the current multiples are constrained by the long stretch of losses.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Narrowing loss trend

Third-quarter 2026 operating loss narrowed to KRW 4.13 billion from a year earlier, and the controlling-shareholder net loss of KRW 3.7 billion was the smallest of the last five quarters. Revenue of KRW 6.69 billion rose 19.3% year on year, a double-digit gain. Compared with the widening losses of 2025, the recent quarters point in an improving direction.

Scale of licensing agreements

The ACP platform at the 66.2%-owned subsidiary signed a licensing deal worth roughly KRW 500 billion, and the mRNA cancer vaccine was announced with milestones of roughly KRW 300 billion.

The company says its partner covers nearly all costs from preclinical work through commercialization, leaving DXVX with little cost burden for those stages. If the deals convert into revenue, the milestones could broaden the revenue base.

Improved balance sheet

Total liabilities at end-2025 were KRW 59.1 billion against total equity of KRW 95.8 billion, and the debt ratio fell to 61.7% from 342.4% in 2024. An August 2026 article, going by its headline, reported that a Hanmi-linked shareholder put KRW 100 billion into DXVX. The funding capacity is wider than before.

09

Bear factors

Persistent losses

Operating losses have run for three consecutive years from 2023 to 2025, and controlling-shareholder net losses for four consecutive years from 2022 to 2025. The 2025 operating margin of -82.8% is the lowest of the four years. Revenue also fell two years in a row, so the improvement in losses is not yet backed by revenue growth.

Delayed licensing results

A March 2025 report said that of roughly 40 items under development since 2022, only one, a diet health food, had reached market. The oral obesity drug is still at the preclinical stage as of November 2026, with an IND target in the second half of 2027.

Licensing announcements have come in succession, but the revenue amounts and timing remain unclear under the deal structures.

Funding reliance and management turnover

A 2025 report said that with most shareholder funds used up, the company took KRW 20 billion in short-term borrowings to secure R&D and operating funds. The board appointed Lee Yong-gu as CEO on September 18, 2026, and a November 4 announcement carried the name of CEO Kim Young-jong.

With operating cash outflows continuing, repeated changes at the top are seen as a weakness in management continuity.

10

Risk factors

Clinical and licensing uncertainty

The oral GLP-1 candidate is preclinical, with an IND target in the second half of 2027. The antiviral candidates show activity only at the cell level, with an IND target in 2029. Several licensing deals have been announced, but without upfront payments, revenue timing could shift widely with stage-gate outcomes.

Financing and funding

Total equity rose to KRW 95.8 billion at end-2025, but operating cash flow was still negative at KRW -18.9 billion. A March 2025 report raised the risk of capital erosion, and the company has used short-term borrowing to cover urgent needs. Any further rights offering would dilute existing shareholders.

Related-party and governance structure

Linking manufacturing and distribution with affiliates such as COREE Group, and the China plan, would both increase transactions with related parties. Several CEO changes in 2026 leave related-party dealings and decision-making independence as key items to examine. The China business relies on the parent's sales network.

11

What to watch next

  1. Late March 2027 (statutory deadline for the annual report)

    The 2026 annual report will formally disclose fourth-quarter 2026 revenue and operating loss, which are not yet in the reported figures, along with full-year cash flow and equity changes. It shows whether quarterly losses in the KRW 4.13 billion to KRW 6.04 billion range persist across the year.

  2. First half 2027

    Whether the OVM-200 cancer vaccine enters Phase 2 and when. Actual entry would show clinical progress; a delay could affect the terms of licensing talks.

  3. Mid-May 2027 (statutory deadline for the Q1 quarterly report)

    Whether first-quarter 2027 revenue holds at 2026 levels and the operating loss stays in the 2026 range. Also whether any licensing milestones appear in revenue.

  4. Second half 2027

    Whether the oral GLP-1 candidate's IND is filed. Filing would move the obesity drug pipeline into clinical development.

12

Overall view

DXVX's revenue peaked at KRW 46.7 billion in 2023 and then fell in 2024 and 2025, while operating losses have run for three consecutive years from 2023. Quarterly revenue has held in the mid-KRW 6 billion range through 2026, while the operating loss has narrowed.

The debt ratio fell to 61.7% at end-2025 from 342.4% a year earlier, yet operating cash outflows continue. Licensing deals worth roughly KRW 500 billion and KRW 300 billion were announced without upfront payments, so the timing and size of revenue depend on stage milestones.

The oral obesity drug, OVM-200 and the antiviral program are all at or before clinical entry, and whether the 2027 targets are met is the next checkpoint. Capital injections from a largest shareholder and frequent CEO changes add uncertainty to management continuity.

This report offers no investment opinion or target price. The key items to follow are the operating loss trend in the annual report and quarterly filings, and whether licensing income appears in revenue.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. smedaily.co.kr
  2. medipana.com
  3. pharm.edaily.co.kr
  4. newsway.co.kr
  5. news.nate.com
  6. dailymedical.kr
  7. hankyung.com
  8. dxvx.com
  9. m.medigatenews.com
  10. ebn.co.kr
  11. rapportian.com
  12. ideal-life.co.kr
  13. newspim.com
  14. newspim.com
  15. thevc.kr
  16. view.asiae.co.kr
  17. m.news.nate.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis